To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7907873.
Insulin glargine (IGlar) 100 U/mL (IGlar-100) is widely used in East Asian countries for the treatment of type 2 diabetes mellitus (T2DM) and is the gold standard of basal insulin treatment. In this review we summarize key information about clinical experience with IGlar-100 in East Asian patients with T2DM, including findings from clinical trials and postmarketing studies. We also provide recommendations and opinions on the optimal use of IGlar-100 in this population. The findings from the studies highlighted in our review indicate that IGlar-100 can be a suitable treatment option for East Asians with T2DM, from initial therapy in combination with oral antihyperglycemic medications through to different combinations and intensification models.
Eli Lilly and Company.
International Diabetes Federation. Brussels, Belgium: IDF; 2017. IDF diabetes atlas—8th edition. https://idf.org/e-library/welcome.html. Accessed 10 Jun 2018.
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49. PubMed
Rossetti P, Ampudia-Blasco FJ, Ascaso JF. Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice. Diabetes Obes Metab. 2014;16:695–706. PubMed
European Medicines Agency. London, UK: EMA; 2009. Lantus summary of product characteristics; 2009 May 8. https://www.ema.europa.eu/documents/product-information/lantus-epar-product-information_en.pdf. Accessed 23 Jan 2018.
Food and Drug Administration. Silver Spring, MD: FDA; 2015. Lantus prescribing information; 2015 Jul. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021081s063lbl.pdf. Accessed 23 Jan 2018.
Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356:443–5. PubMed
Lindsley CW. 2014 global prescription medication statistics: strong growth and CNS well represented. ACS Chem Neurosci. 2015;6:505–6. PubMed
Philippidis A. The top 15 best-selling drugs of 2016. Genet Eng Biotechnol News. 2017 Mar 6. https://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868. Accessed 23 Jan 2018.
Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644–9. PubMed
Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–8. PubMed
Kaku K, Kakuma T, Kono S, Uchimaru H, Shiramoto M, Irie S. Pharmacokinetic and pharmacodynamic analyses on insulin glargine biosimilar in healthy male volunteers using euglycaemic clamp technique. Jpn J Dev Pharmacol Ther. 2016;44:25–34.
Rave K, Nosek L, Heinemann L, Frick A, Becker R. Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers. Diabetes Metab. 2003;29:430–1. PubMed
Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015;17:254–60. PubMed
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9. PubMedPubMedCentral
Fritsche A, Schweitzer MA, Häring MU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138:952–9. PubMed
Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23:1130–6. PubMed
Ju H, Zhao Q, Guo Y, Sun Y, Li C, Huang H. The efficacy of treating newly diagnosed type 2 diabetes with insulin glargine combined with saxagliptin and their effects on function of β-pancreatic cells. Int J Clin Exp Med. 2016;9:4650–4.
Lee JM, Park KS, Park SH, et al. A multi-center, open, randomized, parallel-group, 2-arm study to compare the efficacy and safety of insulin add-on to glimepiride/metformin 1/500 mg b.i.d vs. to glimepiride 4 mg qd in type 2 DM patients with inadequate glycemic control. Diabetes. 2012;61:A280–1.
Moon JS, Ha KS, Yoon JS, Lee HW, Lee HC, Won KC. The effect of glargine vs glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study. Acta Diabetol. 2014;51:277–85. PubMed
Mu PW, Chen YM, Lu HY, et al. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev. 2012;28:236–40. PubMed
Son JW, Lee IK, Woo JT, et al. A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes. Endocr J. 2015;62:1049–57. PubMed
Chien MN, Lee CC, Liu SC, Chen WC, Leung CH, Wang CH. Basal insulin initiation in elderly patients with type 2 diabetes in Taiwan: a comparison with younger patients. Int J Gerontol. 2015;9:142–5.
Chien MN, Chen YL, Hung YJ, et al. Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus (T2D) [abstract]. Diabetes. 2014;63:A600.
Goto H, Hirose T, Shimizu S, et al. Effectiveness of combination therapy with a sulfonylurea and once-daily insulin glargine in Japanese type 2 diabetic patients—evaluation of the long-term (18 months) results of the combination therapy. J Jpn Diabetes Soc. 2007;50:591–7.
Ji L, Zhang P, Zhu D, et al. Comparative effectiveness and safety of different basal insulins in a real-world setting. Diabetes Obes Metab. 2017;19:1116–26. PubMed
Kobayashi M, Tsukube S, Ikeda Y, Shuto Y. Safety and efficacy of combination therapy with insulin glargine and oral hypoglycaemic agents including DPP-4 inhibitors in Japanese T2DM patients: ALOHA 2 Study, a post-marketing surveillance for Lantus. J Diabetes Mellitus. 2014;4:273–89.
Odawara M, Kadowaki T, Naito Y. Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus to Oral Hypoglycemic Agents (ALOHA) study. J Diabetes Complicat. 2015;29:127–33. PubMed
Ohta A, Kato H, Murayama K, et al. Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs. Endocr J. 2014;61:13–8. PubMed
Okayama K, Goto H, Yoshihara T, et al. Effectiveness of step-up bolus insulin addition on combination therapy with sulfonylurea and once-daily insulin glargine in Japanese type 2 diabetic patients (JUN-LAN Study 7). J Jpn Diabetes Soc. 2009;52:197–202.
Suzuki D, Umezono T, Miyauchi M, et al. Effectiveness of basal-supported oral therapy (BOT) using insulin glargine in patients with poorly controlled type 2 diabetes. Tokai J Exp Clin Med. 2012;37:41–6. PubMed
Tsukube S, Kadowaki T, Odawara M. Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan. Diabetol Int. 2016;7:299–307. PubMedPubMedCentral
Ji L, Zhang P, Weng J, et al. Observational registry of basal insulin treatment (ORBIT) in patients with type 2 diabetes uncontrolled by oral hypoglycemic agents in China—study design and baseline characteristics. Diabetes Technol Ther. 2015;17:735–44. PubMed
Ji L, Zhang P, Zhu D, et al. Observational registry of basal insulin treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: real-life use of basal insulin in China. Diabetes Obes Metab. 2017;19:822–30. PubMed
Wulffelé MG, Kooy A, Lehert P, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care. 2002;25:2133–40. PubMed
Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999;130:389–96. PubMed
Kawamori R, Eliaschewitz FG, Takayama H, Hayashida CY. Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;79:97–102. PubMed
Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007;23:919–31. PubMed
Yoshihara T, Kumashiro N, Kanazawa Y, et al. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Endocr J. 2006;53:67–72. PubMed
Kumashiro N, Yoshihara T, Kanazawa Y, et al. Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. Endocr J. 2007;54:163–6. PubMed
Owens DR. Optimizing treatment strategies with insulin glargine in type 2 diabetes. Expert Rev Endocrinol Metab. 2012;7:377–93. PubMed
Yki-Järvinen H, Kauppinen-Mäakelin R, Tikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442–51. PubMed
Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V. Safety and efficacy of glargine compared with NPH insulin for the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med. 2008;25:924–32. PubMed
Home PD, Fritsche A, Schinzel S, Massi-Benedetti M. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab. 2010;12:772–9. PubMed
Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther. 2007;29:1607–19. PubMed
Kawamori R, Iwamoto Y, Kadowaki T, Iwasaki M. Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetic patients. Rinsho Iyaku. 2003;19:445–64.
Wang XL, Lu JM, Pan CY, et al. Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system. Diabetes Res Clin Pract. 2007;76:30–6. PubMed
Pan CY, Sinnassamy P, Chung KD, Kim KW. Insulin glargine vs NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Res Clin Pract. 2007;76:111–8. PubMed
Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal vs lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 vs insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009;32:1007–13. PubMedPubMedCentral
Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26:2034–44. PubMed
Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–5. PubMed
Feng SJ, Li YX. Efficacy and safety of insulin glargine combined with acarbose in the treatment of elder patients with type 2 diabetes. Chin J New Drugs. 2009;1533–4:1544.
Onishi Y, Ono Y, Rabøl R, Endahl L, Nakamura S. Superior glycaemic control with once-daily insulin degludec/insulin aspart vs insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab. 2013;15:826–32. PubMed
Sun Y, Shao L, Niu X, et al. Clinical effectiveness of Novolin 30R vs Lantus combined with Glucobay treatment in elderly patients with type 2 diabetes mellitus controlled by oral hypoglycaemic agents: a randomized study. J Int Med Res. 2014;42:993–1001. PubMed
Tamemoto H, Ikoma A, Saitoh T, Ishikawa SE, Kawakami M. Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes. Diabetes Technol Ther. 2007;9:246–53. PubMed
Yang W, Xu X, Liu X, et al. Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes. Curr Med Res Opin. 2013;29:1599–608. PubMed
Jeong I-K, Chung CH, Zhou Z, et al. Comparison of insulin intensification strategies with insulin lispro low mixture twice daily vs basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus. J Diabetes. 2017;9:396–404. PubMed
Jia W, Xiao X, Ji Q, et al. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. Lancet Diabetes Endocrinol. 2015;3:254–62. PubMed
Jin SM, Kim JH, Min KW, et al. Basal-prandial vs premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: a 24-week randomized non-inferiority trial. J Diabetes. 2016;8:405–13. PubMed
Terauchi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml vs glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab. 2016;18:366–74. PubMedPubMedCentral
Osonoi T, Onishi Y, Nishida T, Hyllested-Winge J, Iwamoto Y. Insulin degludec vs insulin glargine, both once daily as add-on to existing orally administered antidiabetic drugs in insulin-naive Japanese patients with uncontrolled type 2 diabetes: subgroup analysis of a pan-Asian, treat-to-target phase 3 trial. Diabetol Int. 2016;7:141–7. PubMed
Yki-Järvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL vs glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235–43. PubMed
Bolli GB, Riddle MC, Bergenstal RM, Wardecki M, Goyeau H, Home PD. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL vs insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial. Diabetes Metab. 2017;43:351–8. PubMed
Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists vs insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab. 2017;19:216–27. PubMed
Wysham CH, Lin J, Kuritzky L. Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy vs basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis. Postgrad Med. 2017;129:436–45. PubMed
Jones AG, McDonald TJ, Shields BM, et al. Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care. 2016;39:250–7. PubMed
Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab. 2015;17:994–1002. PubMedPubMedCentral
Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther. 2012;34:1892–908. PubMed
Seino Y, Min KW, Niemoeller E, Takami A. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14:910–7. PubMedPubMedCentral
Kaneko S, Oura T, Matsui A, Shingaki T, Takeuchi M. Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes. Endocr J. 2017;64:1165–72. PubMed
Kanazawa Y, Igarashi Y, Komiya K, et al. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2). Endocr J. 2007;54:975–83. PubMed
Suzuki D, Toyoda M, Kondo M, et al. Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes. Tokai J Exp Clin Med. 2012;37:35–40. PubMed
Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Res Clin Pract. 2006;73:35–40. PubMed
Bu S, Guo XH, Yang WY, et al. Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic agents regimen. Zhonghua Yi Xue Za Zhi. 2007;87:3115–8. PubMed
Shigihara N, Tamaki M, Goto H, et al. Efficacy and safety of switching from premix twice daily injection to sulfonylurea and once daily insulin glargine in Japanese type 2 diabetes (JUN-LAN Study 8). J Jpn Diabetes Soc. 2010;53:157–61.
Takahashi H, Sakai K, Kawanishi K, et al. Efficacy of switching from premix analog insulin twice daily injection to insulin glargine once daily injection with sitagliptin. Diabetetol Int. 2015;6:33–8.
Umezono T, Suzuki D, Kuriyama Y, et al. Long-term glycemic control in Japanese type 2 diabetes patients after switching treatment from twice-daily premixed insulin to once daily insulin glargine. Tokai J Exp Clin Med. 2013;38:28–32. PubMed
Yang W, Lv X, Li Q, Jia W, Tian H. A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study. Curr Med Res Opin. 2012;28:533–41. PubMed
Zhang B, Zhao J, Yang W. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study. Diabetes Metab Res Rev. 2017;33:e2863.
Takahara M, Shiraiwa T, Kaneto H, Katakami N, Matsuoka TA, Shimomura I. Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. Endocr J. 2012;59:1131–6. PubMed
Taniguchi M, Tamura M. A multicenter open-label, single-arm, 24-week phase IV study evaluating the effectiveness and safety of treatment of insulin glargine in type 2 diabetes mellitus following glucagon-like peptide-1 (GLP-1) failure (GAUDI Study). Rinsho Iyaku. 2015;9:843–56.
Ohtani T, Ito T. Safety and effectiveness of BOT (Basal supported Oral Therapy) using insulin glargine in Japanese patients with type 2 diabetes-results from post-marketing surveillance of insulin glargine (ALOHA study). Shinyaku To Rinsho (J New Rem Clin). 2011;60:458–75.
Kadowaki T, Ohtani T, Odawara M. Baseline predictive factors for glycemic control in Japanese type 2 diabetes patients treated with insulin glargine plus oral antidiabetic drugs: ALOHA study subanalysis. Diabetol Int. 2013;4:16–22.
Ikeda Y, Tsukube S, Kadowaki T, Odawara M. Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan. Diabetol Int. 2016;7:188–98. PubMed
Odawara M, Ohtani T, Kadowaki T. Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study subanalysis. Diabetes Technol Ther. 2012;14:635–43. PubMed
Odawara M, Kadowaki T, Naito Y. Plasma glucose monitoring and the subsequent HbA1c control in patients with type 2 diabetes on a basal supported oral therapy regimen in real life: subanalysis of the ALOHA study: a 24-week, prospective, open-label, multicenter, observational study. Diabetol Int. 2015;6:66–76.
Brown A, Guess N, Dornhorst A, Taheri S, Frost G. Insulin-associated weight gain in obese type 2 diabetes mellitus patients: what can be done? Diabetes Obes Metab. 2017;19:1655–68. PubMed
The Diabetes Association of the Republic of China (Taiwan). Taipei, Taiwan, ROC: DAROC; 2018. DAROC clinical practice guidelines for diabetes care—2018. http://www.endo-dm.org.tw/dia/direct/. Accessed 27 Jul 2018.
Japan Diabetes Society. Treatment guide for diabetes 2014–2015. Tokyo: JDS; 2017.
Korean Diabetes Association. 2015 treatment guidelines for diabetes. Seoul: KDA; 2017.
Garg SK, Admane K, Freemantle N, et al. Patient-led vs physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study. Endocr Pract. 2015;21:143–57. PubMed
Chan JCN, Bunnag P, Chan SP, et al. Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100units/mL: a patient-level pooled analysis of 16 randomised controlled trials. Diabetes Res Clin Pract. 2018;135:199–205. PubMed
Tamaki M, Shimizu T, Kanazawa A, et al. Effects of changes in basal/total daily insulin ratio in type 2 diabetes patients on intensive insulin therapy including insulin glargine (JUN-LAN Study 6). Diabetes Res Clin Pract. 2008;81:e1–3. PubMed
Araki E, Onishi Y, Asano M, Kim H, Yajima T. Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial. Diabetes Obes Metab. 2017;19:562–70. PubMed
Ishihara H, Yamaguchi S, Nakao I, Okitsu A, Asahina S. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study. Diabetes Obes Metab. 2016;18:1207–16. PubMedPubMedCentral
Araki E, Haneda M, Kasuga M, et al. New glycemic targets for patients with diabetes from the Japan Diabetes Society. J Diabetes Investig. 2017;8:123–5. PubMed
- Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
Kyu Jeung Ahn
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II